You are here: Industry Insights > OrbiMed

News List

HanBio Therapeutics Announces the Completion of a US$40 Million Series A Financing Led by OrbiMed and Hankang Capital prnasia
January 29, 2022
HanBio Therapeutics ("HanBio"), a biotechnology company committed to researching and developing next generation transformative medicines, today announced that it has completed a US$40 million Series...
GentiBio raises $157m to develop Treg therapies for autoimmune diseases pharmaceutical-technology
August 13, 2021
GentiBio has raised $157m in a Series A funding round led by Matrix Capital Management to progress its new pipeline of engineered regulatory T cell (Treg) treatments in immunology.
AnchorDx Completes USD 40 Million Series C Financing to Advance Cancer Screening and Early Detection Programs prnasia
February 23, 2021
AnchorDx Medical Co., Ltd. announced the completion of a USD 40 million Series C financing. This round of financing was jointly led by OrbiMed, a world-renowned biomedicine and healthcare venture capital fund, and WuXi Huiying Investment ...
Evox raises £69.2m to advance exosome-based therapeutics pipeline pharmatimes
February 19, 2021
Oxford-based biotech company Evox Therapeutics has completed a Series C financing round, announcing that it has raised £69.2m ($95.4m) following ‘high demand’ from existing and new investors.
Akeso, Inc. Completes Series-D Private Financing for US$150 Million En-CPhI.CN
November 11, 2019
Akeso, Inc. announced the completion of its Series-D private financing for nearly US$150 million, which was co-led in investment by Loyal Valley Capital ("LVC") and Sino Biopharmaceutical Co. Ltd.
Accusing OrbiMed as co-conspirator in failed coup, Sinovac aborts go-private deal fiercevaccines
July 23, 2018
In a string of bizarre events that involve violence, lawsuits and a high-profile investment shop, Nasdaq-listed Chinese vaccine maker Sinovac has terminated its plan to take the company private.